316 related articles for article (PubMed ID: 15577132)
21. Toremifene: an evaluation of its safety profile.
Harvey HA; Kimura M; Hajba A
Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
[TBL] [Abstract][Full Text] [Related]
22. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
[TBL] [Abstract][Full Text] [Related]
23. Bone builder vs. breast cancer.
Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
[No Abstract] [Full Text] [Related]
24. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
25. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
Legrand E; Hoppé E; Chappard D; Audran M
Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
[TBL] [Abstract][Full Text] [Related]
26. Similarity of uterine mucosa changes in patients treated by raloxifen and tamoxifen.
Willèn R; Willèn H; Lindahl B
Anticancer Res; 2002; 22(2B):1121-5. PubMed ID: 12168910
[TBL] [Abstract][Full Text] [Related]
27. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
Archer DF
Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
[No Abstract] [Full Text] [Related]
28. Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.
Pole JC; Gold LI; Orton T; Huby R; Carmichael PL
Toxicology; 2005 Jan; 206(1):91-109. PubMed ID: 15590111
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene works as well as tamoxifen in preventing invasive breast cancer.
Mayo Clin Womens Healthsource; 2006 Oct; 10(10):3. PubMed ID: 16977270
[No Abstract] [Full Text] [Related]
30. Chemoprevention of breast cancer: recommendations and rationale.
Berg AO;
Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
[No Abstract] [Full Text] [Related]
31. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
32. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
33. Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.
Runowicz CD
Health News; 2003 Apr; 9(4):1-2. PubMed ID: 12710388
[No Abstract] [Full Text] [Related]
34. Safety assessment of raloxifene over eight years in a clinical trial setting.
Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
[TBL] [Abstract][Full Text] [Related]
35. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
36. Microwave endometrial ablation for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Zhu Y; Yang J
J Obstet Gynaecol Res; 2013 Sep; 39(9):1411-4. PubMed ID: 23815697
[TBL] [Abstract][Full Text] [Related]
37. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
38. [SERM].
Nozaki M
Nihon Rinsho; 2006 Sep; 64(9):1645-50. PubMed ID: 16972673
[TBL] [Abstract][Full Text] [Related]
39. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.
Davis AM; Ellersieck MR; Grimm KM; Rosenfeld CS
Mol Reprod Dev; 2006 Aug; 73(8):1034-44. PubMed ID: 16688783
[TBL] [Abstract][Full Text] [Related]
40. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
